Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 13

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  non-alcoholic steatohepatitis
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1
Content available remote

A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis

100%
Grigorescu M., Crisan D., Radu C., Grigorescu M. D., Sparchez Z., Serban A.
Journal of Physiology and Pharmacology
|
2012
|
tom 63
|
nr 4
2
Content available remote

Nanostructure-based therapies for liver fibrosis

100%
Zugravu Pop D. D., Mitrea D. R., Suciu S., Clichici S. V.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 6
3
Content available remote

The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels

100%
Krawczyk M., Gruenhage F., Mahler M., Tirziu S., Acalovschi M., Lammert F.
Journal of Physiology and Pharmacology
|
2011
|
tom 62
|
nr 3
Recently the common adiponutrin (PNPLA3) polymorphism p.I148M has been identified as a genetic determinant of severe forms of non-alcoholic fatty liver disease and alcoholic liver disease. Additionally, insulin resistance - linked to the development of non-alcoholic steatohepatitis - increases the risk of developing gallstones. Here we assessed whether the PNPLA3 p.I148M (c.444 C>G) polymorphism affects glucose and lipid levels and increases gallstone risk. We analysed 229 individuals with gallstones from 108 families (age 24-80 years, BMI 17-55 kg/m2) and 258 gallstone-free controls (age 20-70 years, BMI 14-43 kg/m2). Fasting glucose, triglyceride and cholesterol serum levels were determined. The p.I148M polymorphism was genotyped using a PCR-based assay with 5'-nuclease and fluorescence detection. Case-control association tests and nonparametric linkage (NPL) analysis in sib-pairs were performed. Individuals carrying the [GG] genotype had significantly (P<0.0001) higher median fasting glucose levels as compared to [GC] and [CC] carriers. After adjustment for multiple testing, we detected a trend for an association between triglyceride levels and variant adiponutrin in gallstone patients (P=0.032), and gallstone cases carrying the genotype [CC] presented with significantly higher triglyceride levels than the corresponding controls (P<0.003). No significant effects on cholesterol metabolism were detected. Neither genotype distributions nor NPL scores provided evidence for association or linkage between the PNPLA3 variant and gallstones. In conclusion, homozygous carriers of the PNPLA3 risk allele display higher fasting glucose. Although this adiponutrin variant may affect triglyceride homeostasis, it does not increase the risk of cholelithiasis.
4
Content available remote

Is fatty liver always benign and should not consequently be treated?

80%
Fierbinteanu-Braticevici C., Negreanu L., Tarantino G.
Journal of Physiology and Pharmacology
|
2013
|
tom 64
|
nr 1
5
Content available remote

The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study

80%
Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P. C., Brzozowski T., Konturek S. J.
Journal of Physiology and Pharmacology
|
2012
|
tom 63
|
nr 1
6
Content available remote

The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis

80%
Cichoz-Lach H., Celinski K., Konturek P. C., Konturek S. J., Slomka M.
Journal of Physiology and Pharmacology
|
2010
|
tom 61
|
nr 5
7
Content available remote

Adipohormones as prognostic markers in patients with nonalcoholic steatohepatitis [NASH]

80%
Krawczyk K., Szczesniak P., Kumor A., Jasinska A., Omulecka A., Pietruczuk M., Orszulak-Michalak D., Sporny S., Malecka-Panas E.
Journal of Physiology and Pharmacology. Supplement
|
2009
|
tom 60
|
nr 3
71-75
8
Content available remote

The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin

80%
Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P. C., Brzozowski T., Konturek S. J.
Journal of Physiology and Pharmacology
|
2010
|
tom 61
|
nr 6
9
Content available remote

Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease – 14 months follow up

80%
Celinski K., Konturek P. C., Slomka M., Cichoz-Lach H., Brzozowski T., Konturek S. J., Korolczuk A.
Journal of Physiology and Pharmacology
|
2014
|
tom 65
|
nr 1
10
Content available remote

Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease

80%
Waluga M., Kukla M., Zorniak M., Kajor M., Liszka L., Dyaczynski M., Kowalski G., Zadlo D., Waluga E., Olczyk P., Buldak R. J., Berdowska A., Hartleb M.
Journal of Physiology and Pharmacology
|
2017
|
tom 68
|
nr 3
11
Content available remote

Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis

80%
Surapaneni K. M., Jainu M.
Journal of Physiology and Pharmacology
|
2014
|
tom 65
|
nr 1
12

Expression of genes encoding mitochondrial proteins can distinguish nonalcoholic steatosis from steatohepatitis

80%
Bragoszewski P., Habior A., Walewska-Zielecka B., Ostrowski J.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr 2
In patients without substantial alcohol use, triglyceride accumulation in the liver can lead to nonalcoholic fatty liver disease (NAFLD) that may progress to nonalcoholic steatohepatitis (NASH). The differential diagnosis between NAFLD and NASH can be accomplished only by morphological examination. Although the relationship between mitochondrial dysfunction and the progression of liver pathologic changes has been described, the exact mechanisms initiating primary liver steatosis and its progression to NASH are unknown. We selected 16 genes encoding mitochondrial proteins which expression was compared by quantitative RT-PCR in liver tissue samples taken from patients with NAFLD and NASH. We found that 6 of the 16 examined genes were differentially expressed in NAFLD versus NASH patients. The expression of hepatic HK1, UCP2, ME2, and ME3 appeared to be higher in NASH than in NAFLD patients, whereas HMGCS2 and hnRNPK expression was lower in NASH patients. Although the severity of liver morphological injury in the spectrum of NAFLD-NASH may be defined at the molecular level, expression of these selected 6 genes cannot be used as a molecular marker aiding histological examination. Moreover, it is still unclear whether these differences in hepatic gene expression profiles truly reflect the progression of morphological abnormalities or rather indicate various metabolic and hormonal states in patients with different degrees of fatty liver disease.
13
Content available remote

Therapy of nonalcoholic fatty liver disease: current status

61%
Duvnjak M., Tomasic V., Gomercic M., Smircic Duvnjak L., Barsic N., Lerotic I.
Journal of Physiology and Pharmacology. Supplement
|
2009
|
tom 60
|
nr 7
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.